盐酸缬更昔洛韦片什么时候上市呢？

When will the film be released? In May 2001, the US FDA approved the market. Valcyte hydrochloride is clinically used to treat acute retinitis caused by CMV infection in patients with acquired immunodeficiency syndrome. In May 2003, its indications were expanded. Valcyte hydrochloride is used to prevent and treat secondary CMV infection in organ transplant recipients. On August 11, 2010, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) approved valganciclovir hydrochloride (Valcyte) for the treatment of adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

Induction therapy of CMV retinitis: For patients with active CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Prolonged induction therapy may increase the risk of bone marrow toxicity. Maintenance treatment of CMV retinitis: After induction therapy, or in patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once daily. Induction therapy may be repeated in patients with worsening retinitis. Prevention of CMV infection in transplant patients: For patients who have received solid organ transplants, the recommended dose of Vancevir is 900 mg (two 450 mg tablets) once a day, starting within 10 days after transplantation and continuing until 100 days after transplantation.

Tablet side effects: 1. Hand and foot skin reaction: 70% of patients will experience pain and peeling of hands and feet after taking the medicine for 1 to 4 weeks. You can use: urea ointment for external use. If there is a combined infection, you can use Baiduoban and chlortetracycline ointments. Grind vitamin B6 tablets into powder and mix well with urea cream and apply it on the affected areas of hands and feet for good results. If the pain is severe and you cannot walk, you can suspend or reduce the dose of the drug. 2. For patients with severe leukopenia, neutropenia, anemia and/or thrombocytopenia, it is recommended to use blood cell growth factor treatment and/or consider suspending medication. 3. Skin rash: 20% of patients may develop skin rash on the head, neck, and perineum within 3 to 14 days of taking the drug, which may or may not be accompanied by itching. For a small amount of rash, one tablet of Claritan can be taken orally every day. Extensive rashes require discontinuation of medications and use of dexamethasone for allergy control.